Furthermore, Fig 1C shows that the percentage of CD4+Foxp3+LAP+ T cells was significantly higher in tumor tissues than in non-tumor tissues of CRC patients (12.4%±8.8% vs. 5.5%±3.8%, P  =  0.02). This evidence concerns the gene FOXP3 and colorectal carcinoma.